Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 560131 in AR-V7 positive mCRPC (China, Phase II)
CTR20210933Phase 2Terminated
- Sponsor
- Pyramid Laboratories, Inc.
- Start
- Apr 2021
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AZD5312 in prostate adenocarcinoma, sponsored by Pyramid Laboratories, Inc.. Started Apr 2021; status: terminated.
02
Drugs
AZD5312
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on CTR20210933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210933.